Cargando…

A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling

BACKGROUND: TGFβ1 is a major profibrotic mediator in chronic kidney disease (CKD). Its direct inhibition, however, is limited by adverse effects. Inhibition of activins, also members of the TGFβ superfamily, blocks TGFβ1 profibrotic effects, but the mechanism underlying this and the specific activin...

Descripción completa

Detalles Bibliográficos
Autores principales: Soomro, Asfia, Khajehei, Mohammad, Li, Renzhong, O’Neil, Kian, Zhang, Dan, Gao, Bo, MacDonald, Melissa, Kakoki, Masao, Krepinsky, Joan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885651/
https://www.ncbi.nlm.nih.gov/pubmed/36717814
http://dx.doi.org/10.1186/s11658-023-00424-1
_version_ 1784879973209735168
author Soomro, Asfia
Khajehei, Mohammad
Li, Renzhong
O’Neil, Kian
Zhang, Dan
Gao, Bo
MacDonald, Melissa
Kakoki, Masao
Krepinsky, Joan C.
author_facet Soomro, Asfia
Khajehei, Mohammad
Li, Renzhong
O’Neil, Kian
Zhang, Dan
Gao, Bo
MacDonald, Melissa
Kakoki, Masao
Krepinsky, Joan C.
author_sort Soomro, Asfia
collection PubMed
description BACKGROUND: TGFβ1 is a major profibrotic mediator in chronic kidney disease (CKD). Its direct inhibition, however, is limited by adverse effects. Inhibition of activins, also members of the TGFβ superfamily, blocks TGFβ1 profibrotic effects, but the mechanism underlying this and the specific activin(s) involved are unknown. METHODS: Cells were treated with TGFβ1 or activins A/B. Activins were inhibited generally with follistatin, or specifically with neutralizing antibodies or type I receptor downregulation. Cytokine levels, signaling and profibrotic responses were assessed with ELISA, immunofluorescence, immunoblotting and promoter luciferase reporters. Wild-type or TGFβ1-overexpressing mice with unilateral ureteral obstruction (UUO) were treated with an activin A neutralizing antibody. RESULTS: In primary mesangial cells, TGFβ1 induces secretion primarily of activin A, which enables longer-term profibrotic effects by enhancing Smad3 phosphorylation and transcriptional activity. This results from lack of cell refractoriness to activin A, unlike that for TGFβ1, and promotion of TGFβ type II receptor expression. Activin A also supports transcription through regulating non-canonical MRTF-A activation. TGFβ1 additionally induces secretion of activin A, but not B, from tubular cells, and activin A neutralization prevents the TGFβ1 profibrotic response in renal fibroblasts. Fibrosis induced by UUO is inhibited by activin A neutralization in wild-type mice. Worsened fibrosis in TGFβ1-overexpressing mice is associated with increased renal activin A expression and is inhibited to wild-type levels with activin A neutralization. CONCLUSIONS: Activin A facilitates TGFβ1 profibrotic effects through regulation of both canonical (Smad3) and non-canonical (MRTF-A) signaling, suggesting it may be a novel therapeutic target for preventing fibrosis in CKD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s11658-023-00424-1.
format Online
Article
Text
id pubmed-9885651
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98856512023-01-31 A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling Soomro, Asfia Khajehei, Mohammad Li, Renzhong O’Neil, Kian Zhang, Dan Gao, Bo MacDonald, Melissa Kakoki, Masao Krepinsky, Joan C. Cell Mol Biol Lett Research BACKGROUND: TGFβ1 is a major profibrotic mediator in chronic kidney disease (CKD). Its direct inhibition, however, is limited by adverse effects. Inhibition of activins, also members of the TGFβ superfamily, blocks TGFβ1 profibrotic effects, but the mechanism underlying this and the specific activin(s) involved are unknown. METHODS: Cells were treated with TGFβ1 or activins A/B. Activins were inhibited generally with follistatin, or specifically with neutralizing antibodies or type I receptor downregulation. Cytokine levels, signaling and profibrotic responses were assessed with ELISA, immunofluorescence, immunoblotting and promoter luciferase reporters. Wild-type or TGFβ1-overexpressing mice with unilateral ureteral obstruction (UUO) were treated with an activin A neutralizing antibody. RESULTS: In primary mesangial cells, TGFβ1 induces secretion primarily of activin A, which enables longer-term profibrotic effects by enhancing Smad3 phosphorylation and transcriptional activity. This results from lack of cell refractoriness to activin A, unlike that for TGFβ1, and promotion of TGFβ type II receptor expression. Activin A also supports transcription through regulating non-canonical MRTF-A activation. TGFβ1 additionally induces secretion of activin A, but not B, from tubular cells, and activin A neutralization prevents the TGFβ1 profibrotic response in renal fibroblasts. Fibrosis induced by UUO is inhibited by activin A neutralization in wild-type mice. Worsened fibrosis in TGFβ1-overexpressing mice is associated with increased renal activin A expression and is inhibited to wild-type levels with activin A neutralization. CONCLUSIONS: Activin A facilitates TGFβ1 profibrotic effects through regulation of both canonical (Smad3) and non-canonical (MRTF-A) signaling, suggesting it may be a novel therapeutic target for preventing fibrosis in CKD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s11658-023-00424-1. BioMed Central 2023-01-30 /pmc/articles/PMC9885651/ /pubmed/36717814 http://dx.doi.org/10.1186/s11658-023-00424-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Soomro, Asfia
Khajehei, Mohammad
Li, Renzhong
O’Neil, Kian
Zhang, Dan
Gao, Bo
MacDonald, Melissa
Kakoki, Masao
Krepinsky, Joan C.
A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title_full A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title_fullStr A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title_full_unstemmed A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title_short A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
title_sort therapeutic target for ckd: activin a facilitates tgfβ1 profibrotic signaling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885651/
https://www.ncbi.nlm.nih.gov/pubmed/36717814
http://dx.doi.org/10.1186/s11658-023-00424-1
work_keys_str_mv AT soomroasfia atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT khajeheimohammad atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT lirenzhong atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT oneilkian atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT zhangdan atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT gaobo atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT macdonaldmelissa atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT kakokimasao atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT krepinskyjoanc atherapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT soomroasfia therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT khajeheimohammad therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT lirenzhong therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT oneilkian therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT zhangdan therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT gaobo therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT macdonaldmelissa therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT kakokimasao therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling
AT krepinskyjoanc therapeutictargetforckdactivinafacilitatestgfb1profibroticsignaling